Skip to main content
placeholder image

Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Vasselli, J. R., Frentzas, S., Weickhardt, A. J., de Souza, P. L., Tang, J., Wyant, T., . . . Knickerbocker, A. (2022). Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), tps2671. doi:10.1200/jco.2022.40.16_suppl.tps2671

Web Of Science Accession Number


Start Page


  • tps2671

End Page


  • tps2671

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2022

Citation


  • Vasselli, J. R., Frentzas, S., Weickhardt, A. J., de Souza, P. L., Tang, J., Wyant, T., . . . Knickerbocker, A. (2022). Trial in progress: A phase 1-2, first-in-human, open label, dose escalation and expansion study of AU-007, a monoclonal antibody that binds to IL-2 and inhibits IL-2R�� binding, in patients with advanced solid tumors.. Journal of Clinical Oncology, 40(16_suppl), tps2671. doi:10.1200/jco.2022.40.16_suppl.tps2671

Web Of Science Accession Number


Start Page


  • tps2671

End Page


  • tps2671

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication